| Today’s Big NewsMar 1, 2024 |
|
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now. |
|
| By Kevin Dunleavy Less than three weeks after a Texas judge tossed a lawsuit by industry lobbying group PhRMA which challenged the constitutionality of the Inflation Reduction Act, a federal court in Delaware has done the same with a similar action brought by AstraZeneca. |
|
|
|
By Gabrielle Masson After investing heavily in COVID-19 over the last few years, Pfizer is pivoting to zoom in on cancer, with a laser focus on next-gen antibody-drug conjugates, small molecules and bispecific antibodies. |
By Max Bayer Moderna is laying off some employees within its manufacturing unit after shaving COVID production costs. The company previously disclosed plans to rightsize its COVID vaccine production footprint. |
By Conor Hale Boston Scientific has received FDA approval for its Agent drug-coated balloon sized to fit within blocked or constricted coronary arteries, nearly a decade after it made its European debut. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By Kevin Dunleavy It’s time to add another vaccine to the shortage list in the United States as the CDC has urged healthcare providers to conserve their supply of tetanus shots. The warning from the national public health agency comes after one of the two providers of tetanus shots in the U.S., MassBiologics, discontinued production of its tetanus and diphtheria vaccine. |
By Max Bayer We all aspire to have a boss who will just give you money for your next endeavor. Mathai Mammen, M.D., Ph.D., happens to have just that. J&J’s former pharma R&D chief, now the CEO of FogPharma, has brought on former J&J CEO Alex Gorsky as an investor in the company’s $145 million series E. |
By Conor Hale Artificial intelligence is once again the name of the game, this time at the annual meeting of the European Congress of Radiology being held in Vienna, Austria. |
By Zoey Becker The company's supervisory board proposed the appointments of activist investor Jeffrey Ubben, legal expert Lori Schecter and biotech leader Nancy Simonian, M.D. Bayer also swapped in a new head of its consumer health division. |
By Annalee Armstrong PTC Therapeutics has managed to slash through the regulatory jungle to find a path forward for Friedreich ataxia med vatiquinone after a pair of failures last year left the biotech reeling. |
By Conor Hale The series C round, led by Sands Capital, includes an initial closing of $100 million, with the remaining $28 million expected to come in the next month, the company said. |
By Gabrielle Masson Karuna Therapeutics is “vigorously” denying any deficiencies with a proxy statement filed last month that has become the focus of a shareholder lawsuit, though the biotech is producing supplemental information to address several of the allegations raised. |
Fierce podcasts Don’t miss an episode |
| The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This week on "The Top Line," Fierce Pharma’s Angus Liu talks with regulatory experts to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line. |
|
|---|
|
|
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
